PRESS RELEASE

MITHRA ANNOUNCES 2018 FINANCIAL CALENDAR

Liège, Belgium 17 January 2018 - Mithra (Euronext Brussels: MITRA), a company focused on women's

health, today announces its financial calendar for 2018:

  • - 2 March 2018: Full Year Results 2017

  • - 16 April 2018: Annual Report 2017

  • - 17 May 2018: Annual General Meeting 2018

  • - 25 September 2018: Half Year Results 2018

This schedule is indicative and subject to change.

The calendar is also available on Mithra's Investor website:investors.mithra.com.

For more information, please contact:

Investor Relations

Sofie Van Gijsel, IRO +32 485 19 14 15investorrelations@mithra.comsvangijsel@mithra.com

Press

Julie Dessart

Chief Communication Officer +32 4 349 28 22 / +32 475 86 41 75press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta®- are built on Mithra's unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO. Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart and is headquartered in Liège, Belgium. Further information can be found at:www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's mailing list, visitinvestors.mithra.com

Mithra Pharmaceuticals SA published this content on 17 January 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 17 January 2018 16:54:07 UTC.

Original documenthttps://investors.mithra.com/wp-content/uploads/2018/01/2018-01-17-Financial-Calendar-2018-EN.pdf

Public permalinkhttp://www.publicnow.com/view/C174B9E499860EECAED141330401934EE1A15744